Ignet

Gene Information

Gene symbol: ERAL1

Gene name: Era G-protein-like 1 (E. coli)

HGNC ID: 3424

Synonyms: HERA-B

Related Genes

#	Gene Symbol	Number of hits
1	BCL2	1 hits
2	C21orf63	1 hits
3	CPZ	1 hits
4	CSF1	1 hits
5	CSF2	1 hits
6	EPHB6	1 hits
7	ESR2	1 hits
8	GCY	1 hits
9	IFNG	1 hits
10	IL10	1 hits
11	IL17A	1 hits
12	IL1B	1 hits
13	IL1R1	1 hits
14	IL2	1 hits
15	IL6	1 hits
16	IL8	1 hits
17	SFTPC	1 hits
18	TGFB1	1 hits
19	TNF	1 hits
20	VHLL	1 hits

Related Sentences

#	PMID	Sentence
1	1254701	The replication of seven rabies virus strains (CVS, HEP, PV, ERA, WIRAB, CPZ and BOLIVAR) in BHK cells and the inactivation dynamics of these strains by beta-propiolactone, acetylethylenimine, and ethylenimine were studied to find the most immunogenic strain and the most economic and stable inactivating agent for the production of an inactivated tissue culture rabies vaccine for animal use.
2	2641836	The ERA anti-rabies vaccine protected 100% of all the mice challenged with C/SP, C/NG and DR-19 strains and 83% of those challenged with CVS.
3	4628958	Although both the HEP and ERA viruses infected Vero and BHK-21 cells, the amount of fluorescent antigen observed was most consistent with ERA virus and BHK-21 cells.
4	7979981	The amino acid sequence homologies of strain Vnukovo-32 were compared with fixed strains ERA, SAD B19, PV, HEP-Flury, CVS and two street strains, canine and CXX89-1, were 98.9% (6 replacements), 98.3% (9), 96.2% (20), 91.4% (45), 87.0% (68), 93.5% (34) and 91.4% (45), respectively.
5	8577283	Among four rabies virus strains tested, the antigenicity to MAb RG719 was absent from the Nishigahara strain, while the other three strains (HEP, ERA and CVS) reacted to the MAb.
6	14554083	ERA infection and production were similar in Jurkat-vect and Jurkat-Bcl-2 cells, indicating Bcl-2 has no direct antiviral effects.
7	14554083	Bcl-2 production is naturally upregulated by day 3 in ERA-infected Jurkat-vect cultures.
8	14554083	ERA infection and production were similar in Jurkat-vect and Jurkat-Bcl-2 cells, indicating Bcl-2 has no direct antiviral effects.
9	14554083	Bcl-2 production is naturally upregulated by day 3 in ERA-infected Jurkat-vect cultures.
10	20130130	Peripheral blood mononuclear cells (PBMCs) from healthy donor women were stimulated in vitro with HPV-16 VLPs (2.5 microg/ml) in the presence of E2 and P4 administered either alone or in combination; and lymphoproliferation, cytokine production, transcription factor expression, and steroid hormone receptor expression were analyzed.
11	20130130	HPV-16 VLPs significantly increased the levels of lymphoproliferation, proinflammatory cytokine (gamma interferon [IFN-gamma], interleukin-1beta [IL-1beta], IL-2, IL-6, IL-8, IL-12p70, IL-17, tumor necrosis factor alpha [TNF-alpha]) production, anti-inflammatory cytokine (IL-1ra, IL-10) production, and the expression of Eralpha and Erbeta but decreased the levels of Foxp3 expression and production of transforming growth factor beta (TGF-beta).
12	20130130	Exposure of PBMCs to E2 and P4 either alone or in combination significantly decreased the levels of lymphoproliferation and production of proinflammatory cytokines (IFN-gamma, IL-12p70, TNF-alpha) but increased the levels of production of IL-10 and TGF-beta and the expression of Foxp3 in response to HPV-16 VLPs.
13	25549617	The results showed that both local mucosal and systemic immune responses against LT, STa, STb, and F41 were induced in BALB/c mice immunized orally with the recombinant E. coli strains ER-A and ER-B simultaneously.
14	25549617	These data indicated that the use of recombinant E. coli ER-A and ER-B could be a valuable strategy for future polyvalent vaccine development of ETEC.
15	25549617	The results showed that both local mucosal and systemic immune responses against LT, STa, STb, and F41 were induced in BALB/c mice immunized orally with the recombinant E. coli strains ER-A and ER-B simultaneously.
16	25549617	These data indicated that the use of recombinant E. coli ER-A and ER-B could be a valuable strategy for future polyvalent vaccine development of ETEC.
17	25768031	To develop a more effective and safe vaccine against rabies, we have constructed a chimeric rabies virus-like particle (VLP), which containing glycoprotein (G) and matrix protein (M) of rabies virus (RABV) Evelyn-Rokitnicki-Abelseth (ERA) strain, and membrane-anchored granulocyte-macrophage colony-stimulating factor (GM-CSF), and it was named of EVLP-G.
18	25768031	The EVLP-G also elicited significantly more IFN-γ- or IL-4-secreting CD4+ and CD8+ T cells than the sRVLP.